TOL Stock Overview
Toleranzia AB, a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases.
Toleranzia AB Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||kr0.95|
|52 Week High||kr1.48|
|52 Week Low||kr0.82|
|1 Month Change||-2.66%|
|3 Month Change||-7.32%|
|1 Year Change||-35.37%|
|3 Year Change||-80.85%|
|5 Year Change||-80.96%|
|Change since IPO||-89.50%|
Recent News & Updates
|TOL||SE Biotechs||SE Market|
Return vs Industry: TOL underperformed the Swedish Biotechs industry which returned -30.9% over the past year.
Return vs Market: TOL underperformed the Swedish Market which returned -29.4% over the past year.
|TOL Average Weekly Movement||8.1%|
|Biotechs Industry Average Movement||8.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in SE Market||11.8%|
|10% least volatile stocks in SE Market||4.3%|
Stable Share Price: TOL is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: TOL's weekly volatility (8%) has been stable over the past year.
About the Company
Toleranzia AB, a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate for treating myasthenia gravis, an autoimmune nerve and muscle disease. It also intends to develop TOL3 drug candidate to treat ANCA vasculitis, an autoimmune blood vessel disease.
Toleranzia AB Fundamentals Summary
|TOL fundamental statistics|
Is TOL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TOL income statement (TTM)|
|Cost of Revenue||kr0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Oct 28, 2022
|Earnings per share (EPS)||-0.068|
|Net Profit Margin||-23.03%|
How did TOL perform over the long term?See historical performance and comparison